These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 22406277)

  • 1. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
    Woolpert T; Staples JE; Faix DJ; Nett RJ; Kosoy OI; Biggerstaff BJ; Johnson BW; Sracic M; Fischer M
    Vaccine; 2012 Apr; 30(20):3090-6. PubMed ID: 22406277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response at 12-23 months following a single dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
    Krow-Lucal ER; Laven J; Perry L; Biggerstaff BJ; Johnson BW; Hollis E; Fischer M; Woolpert T; Hills SL
    Vaccine; 2020 Oct; 38(44):6899-6903. PubMed ID: 32907756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
    Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 May; 60(20):661-3. PubMed ID: 21617632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
    Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated).
    Kikukawa A; Gomi Y; Akechi M; Onishi T; Manabe S; Namazue J; Fuke I; Ishikawa T; Okuno Y; Ueda S
    Vaccine; 2012 Mar; 30(13):2329-35. PubMed ID: 22306856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines.
    Erra EO; Askling HH; Rombo L; Riutta J; Vene S; Yoksan S; Lindquist L; Pakkanen SH; Huhtamo E; Vapalahti O; Kantele A
    Clin Infect Dis; 2012 Sep; 55(6):825-34. PubMed ID: 22696017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of single-dose Vero cell-derived Japanese encephalitis vaccine in Japanese adults.
    Takeshita N; Lim CK; Mizuno Y; Shimbo T; Kotaki A; Ujiie M; Hayakawa K; Kato Y; Kanagawa S; Kaku M; Takasaki T
    J Infect Chemother; 2014 Apr; 20(4):238-42. PubMed ID: 24485326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity.
    Reisler RB; Danner DK; Gibbs PH
    Vaccine; 2010 Mar; 28(12):2436-41. PubMed ID: 20060946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand.
    Chotpitayasunondh T; Sohn YM; Yoksan S; Min J; Ohrr H
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S195-203. PubMed ID: 22043776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
    Erra EO; Kantele A
    Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan.
    Yang SE; Pan MJ; Tseng HF; Liau MY
    Vaccine; 2006 Mar; 24(14):2669-73. PubMed ID: 16314007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.
    Schuller E; Jilma B; Voicu V; Golor G; Kollaritsch H; Kaltenböck A; Klade C; Tauber E
    Vaccine; 2008 Aug; 26(34):4382-6. PubMed ID: 18599165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Needle-free jet injection of small doses of Japanese encephalitis DNA and inactivated vaccine mixture induces neutralizing antibodies in miniature pigs and protects against fetal death and mummification in pregnant sows.
    Imoto J; Ishikawa T; Yamanaka A; Konishi M; Murakami K; Shibahara T; Kubo M; Lim CK; Hamano M; Takasaki T; Kurane I; Udagawa H; Mukuta Y; Konishi E
    Vaccine; 2010 Oct; 28(46):7373-80. PubMed ID: 20851083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.